National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa.

Dinh A, Bleibtreu A, Duran C, Bouchand F, Bosch A, Crozon-Clauzel J, Roncato-Saberan M, Matt M, Boibieux A, Fanton A, Wille H, Fiaux E, Pilmis B, Lacoste M, Saint-Genis Q, Thumerelle C, Pavese P, Vuotto F, Senneville E, Potron A, Corvec S, Boutoille D, Jeannot K, Dortet L, On Behalf Of The Meropenem-Vaborbactam French Study Group

Open source

DOI: 10.3390/antibiotics13121152
Published: 2024 Dec 1
Container: Antibiotics (Basel, Switzerland)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/antibiotics13121152,
  title = {National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa.},
  author = {Dinh A and Bleibtreu A and Duran C and Bouchand F and Bosch A and Crozon-Clauzel J and Roncato-Saberan M and Matt M and Boibieux A and Fanton A and Wille H and Fiaux E and Pilmis B and Lacoste M and Saint-Genis Q and Thumerelle C and Pavese P and Vuotto F and Senneville E and Potron A and Corvec S and Boutoille D and Jeannot K and Dortet L and On Behalf Of The Meropenem-Vaborbactam French Study Group},
  year = {2024},
  journal = {Antibiotics (Basel, Switzerland)},
  doi = {10.3390/antibiotics13121152},
  url = {https://doi.org/10.3390/antibiotics13121152}
}

RIS

TY  - JOUR
TI  - National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa.
AU  - Dinh A
AU  - Bleibtreu A
AU  - Duran C
AU  - Bouchand F
AU  - Bosch A
AU  - Crozon-Clauzel J
AU  - Roncato-Saberan M
AU  - Matt M
AU  - Boibieux A
AU  - Fanton A
AU  - Wille H
AU  - Fiaux E
AU  - Pilmis B
AU  - Lacoste M
AU  - Saint-Genis Q
AU  - Thumerelle C
AU  - Pavese P
AU  - Vuotto F
AU  - Senneville E
AU  - Potron A
AU  - Corvec S
AU  - Boutoille D
AU  - Jeannot K
AU  - Dortet L
AU  - On Behalf Of The Meropenem-Vaborbactam French Study Group
PY  - 2024
JO  - Antibiotics (Basel, Switzerland)
DO  - 10.3390/antibiotics13121152
UR  - https://doi.org/10.3390/antibiotics13121152
ER  -

APA

A, D., A, B., C, D., F, B., A, B., J, C., M, R., M, M., A, B., A, F., H, W., E, F., B, P., M, L., Q, S., C, T., P, P., F, V., E, S., A, P., S, C., D, B., K, J., L, D., & Group, O. B. O. T. M. F. S. (2024). National Cohort of Compassionate Use of Meropenem-Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa.. Antibiotics (Basel, Switzerland). https://doi.org/10.3390/antibiotics13121152

Source records

pubmed · retrieved 2026-09-25T11:33:43.559Z